ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma
Status:
Completed
Trial end date:
2018-08-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of the combination treatment
of doxorubicin, cyclophosphamide, bortezomib, dexamethasone, and lenalidomide in newly
diagnosed multiple myeloma patients.